Skip to main content

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Completed · Phase 3 · NCT03626688

Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease

At a glance

Research payments reported, 2025
$1.8M
U.S. investigators named
51
Sites paid
50
Planned or actual enrollment
687

About the trial

Sponsor
United Therapeutics
Tested
Ralinepag (drug), Placebo (drug)
Dates
Started 2019-01-24; completion 2025-12-31
Results posted
Not yet

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.

From ClinicalTrials.gov, last updated 2026-06-16. Full record, eligibility and contacts (opens in a new tab)

Industry funding

United Therapeutics Corporation reported $1.8M in research payments for this study in 2025 (486 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.